North Tide Capital’s Impax Laboratories, Inc. IPXL Stock Holding History

North Tide Capital’s Portfolio IPXL Stock Details IPXL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-1,000,000	Closed	-$16.1M	–	15
2017 Q2	$16.1M	Sell	1,000,000 -2,000,000	-67%	-$29.5M	3.58%	10
2017 Q1	$38M	Buy	3,000,000 +1,000,000	+50%	+$12.1M	5.83%	9
2016 Q4	$26.5M	Buy	+2,000,000	New	+$34.2M	4.53%	8

Other funds holding IPXL

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

Fosun International Hong Kong, China $399M AUM 16.11% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

North Tide Capital's IPXL Position: Q3 2017 in Review

North Tide Capital sold out of Impax Laboratories, Inc. (IPXL) in Q3 2017, closing a stake of 1,000,000 shares — an estimated $16.1M sold.

North Tide Capital first reported a position in IPXL in Q4 2016 and held it in 3 quarters. The position peaked at $38M in Q1 2017. 189 funds tracked by Wall St. Rank hold IPXL as of Q3 2017.

North Tide Capital reported no remaining Impax Laboratories, Inc. position as of Q3 2017 after selling out during the quarter.
North Tide Capital sold 1,000,000 Impax Laboratories, Inc. shares in Q3 2017, an estimated $16.1M.
North Tide Capital first reported a position in Impax Laboratories, Inc. in Q4 2016 and held it in 3 quarters.
North Tide Capital's Impax Laboratories, Inc. position peaked at $38M in Q1 2017.
189 funds tracked by Wall St. Rank held Impax Laboratories, Inc. as of Q3 2017.

Based on North Tide Capital's 13F filing for Q3 2017, filed 14 Nov 2017.